8-K
PRO DEX INC (PDEX)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the SecuritiesExchange Act of 1934
Date of Report (Date of earliest event reported): May 5, 2022
PRO-DEX, INC.
(Exact name of registrant as specified in charter)
| Colorado | 0-14942 | 84-1261240 |
|---|---|---|
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification Number) |
2361 McGaw Avenue
Irvine, California 92614
(Address of principal executive offices, zipcode)
(949) 769-3200
(Registrant’s telephone number includingarea code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Exchange Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock, no par value | PDEX | NASDAQ Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
| Emerging growth company ☐ |
|---|
If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02. | Results of Operations and Financial Condition. |
|---|
The information in this Item 2.02 of this Form 8-K, as well as Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
On May 5, 2022, Pro-Dex, Inc. (the “Company”) is issuing a press release announcing its financial performance for the third quarter and nine months ended March 31, 2022. A copy of the press release is attached to this Form 8-K as Exhibit 99.1, which is incorporated herein by this reference.
| Item 9.01 | Financial Statements and Exhibits. |
|---|
(d) Exhibits
| Exhibit Number | Description |
|---|---|
| 99.1 | Press Release dated May 5, 2022. |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: May 5, 2022 | Pro-Dex, Inc. | |
|---|---|---|
| By: | /s/ Alisha K. Charlton | |
| Alisha K. Charlton | ||
| Chief Financial Officer |
INDEX TO EXHIBITS
| Exhibit Number | Description |
|---|---|
| 99.1 | Press Release dated May 5, 2022. |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) |
EXHIBIT 99.1
Contact: Richard L. Van Kirk, Chief Executive Officer
(949) 769-3200
For Immediate Release
PRO-DEX, INC. ANNOUNCES FISCAL 2022 THIRD QUARTER
AND NINE-MONTH RESULTS
IRVINE, CA, May 5, 2022 - PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its fiscal 2022 third quarter ended March 31, 2022. The Company also filed its Quarterly Report on Form 10-Q for the third quarter of fiscal year 2022 with the Securities and Exchange Commission today.
Quarter Ended March 31, 2022
Net sales for the three months ended March 31, 2022, decreased $2.5 million, or 21%, to $9.3 million from $11.7 million for the three months ended March 31, 2021, due primarily to decreased sales of $2.8 million of our thoracic driver, which is as expected after a significant launch and fulfillment of our customer’s distribution network. While we expect future sales of this product, the revenue may not follow a consistent trajectory.
Gross profit for the three months ended March 31, 2022, decreased $1.5 million, or 35%, to $2.9 million from $4.4 million for the same period in fiscal 2021. The gross profit decrease is related in part to procurement of long-lead time components for many of our printed circuit board assemblies at higher prices given the world-wide shortages of these parts. These components were necessary to support customer requirements. As an example, a component normally costing $5 each was available at only $70 each due to these shortages. Total non-standard component costs were approximately $340,000 for the third quarter. While this remains an issue, we are hopeful that the most challenging cost issues are behind us.
Operating expenses (which include selling, general and administrative, and research and development expenses) for the quarter ended March 31, 2022, decreased $683,000, or 27%, compared to the same period in fiscal 2021 mostly due to reduced spending on internal product development projects as our engineering team focused more on billable customer projects.
Net income for the quarter ended March 31, 2022, was $462,000, or $0.12 per diluted share, compared to $2.1 million, or $0.54 per diluted share, for the corresponding quarter in fiscal 2021. Net income for the quarter ended March 31, 2021, included $919,000 of combined realized and unrealized gains on our investment portfolio, while the quarter ended March 31, 2022, included unrealized losses of $275,000.
Nine Months Ended March31, 2022
Net sales for the nine months ended March 31, 2022, increased $832,000, or 3%, to $29.4 million from $28.6 million for the nine months ended March 31, 2021, due to increased billable non-recurring engineering projects and despite the above mentioned component challenges.
Gross profit for the nine months ended March 31, 2022, decreased $767,000, or 7%, compared to the same period in fiscal 2021. The gross profit decline for the nine months ended March 31, 2022, is similarly due to the supply chain issues mentioned above.
Operating expenses (which include selling, general and administrative, and research and development expenses) for the nine months ended March 31, 2022, decreased 12% to $5.7 million from $6.5 million in the prior fiscal year’s corresponding period, mostly due to reduced spending on internal product development projects and reduced selling expenses offset by increased general and administrative expenses due to non-cash stock based compensation expense.
Net income for the nine months ended March 31, 2022 was $2.5 million, or $0.65, per diluted share, compared to $5.0 million, or $1.26 per diluted share, for the corresponding period in fiscal 2021. Net income for the nine months ended March 31, 2021, included $2.2 million of combined realized and unrealized gains on our investment portfolio, while the nine months ended March 31, 2022, included unrealized losses of $427,000.
CEO Comments
“As disclosed in our second quarter earnings release, we knew that we were facing supply chain challenges related to component shortages and we are pleased that while this quarter did not set any records, we were able to meet our customers’ expectations and report profitable results during this challenging period,” said the Company’s President and Chief Executive Officer Richard L. (“Rick”) Van Kirk. “While we are still sourcing parts that have proven difficult and costly to obtain, we have successfully navigated these sourcing challenges. We are looking forward to a good fourth quarter and we are tracking toward record sales for the fiscal year from a revenue perspective as we have a healthy backlog and have secured the components we need. We also have absorbed much of the additional component costs in our third quarter. We remain optimistic going forward as we have a healthy pipeline and the additional capacity our new building provides.
About Pro-Dex, Inc.:
Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. We have patented adoptive torque-limiting software and proprietary sealing solutions which appeal to our customers, primarily medical device distributors. Pro-Dex also manufactures and sells rotary air motors to a wide range of industries. Pro-Dex's products are found in hospitals and medical engineering labs around the world. For more information, visit the Company's website at www.pro-dex.com.
Statements herein concerning the Company's plans, growth, and strategies may include 'forward-looking statements' within the context of the federal securities laws. Statements regarding the Company's future events, developments, and future performance, (including, but not limited to, future sale of products and the ability to navigate future supply chain challenges), as well as management's expectations, beliefs, plans, estimates, or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company's actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business concerns of the Company set forth in the Company's filings with the Securities and Exchange Commission.
(tables follow)
PRO-DEX, INC. ANDSUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands, except share amounts)
| June 30,<br><br> <br>2021 | |||
|---|---|---|---|
| ASSETS | |||
| Current Assets: | |||
| Cash and cash equivalents | 4,761 | $ | 3,721 |
| Investments | 1,129 | 1,295 | |
| Accounts receivable, net of allowance for doubtful accounts of 0 and 2 at March 31, 2022 and at June 30, 2021, respectively | 8,680 | 10,933 | |
| Deferred costs | 341 | 193 | |
| Inventory | 11,866 | 8,437 | |
| Prepaid expenses and other current assets | 1,322 | 434 | |
| Total current assets | 28,099 | 25,013 | |
| Land and building, net | 6,366 | 6,437 | |
| Equipment and leasehold improvements, net | 4,635 | 3,845 | |
| Right of use asset, net | 2,339 | 2,605 | |
| Intangibles, net | 162 | 186 | |
| Deferred income taxes, net | 463 | 463 | |
| Investments | 1,778 | 1,704 | |
| Other assets | 42 | 67 | |
| Total assets | 43,884 | $ | 40,320 |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | |||
| Current Liabilities: | |||
| Accounts payable | 3,533 | $ | 2,288 |
| Accrued expenses | 1,652 | 2,198 | |
| Deferred revenue | 896 | 150 | |
| Note payable | 1,642 | 1,236 | |
| Total current liabilities | 7,723 | 5,872 | |
| Lease liability, net of current portion | 2,151 | 2,432 | |
| Income taxes payable | 1,164 | 397 | |
| Notes payable, net of current portion | 10,575 | 11,535 | |
| Total non-current liabilities | 13,890 | 14,364 | |
| Total liabilities | 21,613 | 20,236 | |
| Shareholders’ equity: | |||
| Common shares; no par value; 50,000,000 shares authorized; 3,618,663 and 3,645,660 shares issued and outstanding at March 31, 2022 and June 30, 2021, respectively | 7,690 | 7,953 | |
| Retained earnings | 14,581 | 12,131 | |
| Total shareholders’ equity | 22,271 | 20,084 | |
| Total liabilities and shareholders’ equity | 43,884 | $ | 40,320 |
All values are in US Dollars.
PRO-DEX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
(In thousands, except per share amounts)
| Three Months EndedMarch 31, | Nine Months EndedMarch 31, | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | 2021 | 2022 | 2021 | |||||||||
| Net sales | $ | 9,265 | $ | 11,739 | $ | 29,426 | $ | 28,594 | ||||
| Cost of sales | 6,407 | 7,354 | 19,737 | 18,138 | ||||||||
| Gross profit | 2,858 | 4,385 | 9,689 | 10,456 | ||||||||
| Operating expenses: | ||||||||||||
| Selling expenses | 20 | 136 | 79 | 415 | ||||||||
| General and administrative expenses | 1,145 | 1,280 | 3,402 | 2,922 | ||||||||
| Loss on disposal of equipment | 14 | — | 14 | — | ||||||||
| Research and development costs | 658 | 1,104 | 2,254 | 3,184 | ||||||||
| Total operating expenses | 1,837 | 2,520 | 5,749 | 6,521 | ||||||||
| Operating income | 1,021 | 1,865 | 3,940 | 3,935 | ||||||||
| Interest expense | (112 | ) | (102 | ) | (349 | ) | (231 | ) | ||||
| Unrealized gain (loss) on marketable equity investments | (275 | ) | 136 | (427 | ) | 1,442 | ||||||
| Interest and other income | — | 41 | 50 | 102 | ||||||||
| Gain on sale of investments | — | 783 | — | 795 | ||||||||
| Income before income taxes | 634 | 2,723 | 3,214 | 6,043 | ||||||||
| Income tax expense | (172 | ) | (592 | ) | (764 | ) | (1,004 | ) | ||||
| Net income | $ | 462 | $ | 2,131 | $ | 2,450 | $ | 5,039 | ||||
| Basic net income per share: | ||||||||||||
| Net income | $ | 0.13 | $ | 0.56 | $ | 0.67 | $ | 1.31 | ||||
| Diluted net income per share: | ||||||||||||
| Net income | $ | 0.12 | $ | 0.54 | $ | 0.65 | $ | 1.26 | ||||
| Weighted average common shares outstanding: | ||||||||||||
| Basic | 3,626 | 3,817 | 3,645 | 3,843 | ||||||||
| Diluted | 3,749 | 3,966 | 3,774 | 3,998 | ||||||||
| Common shares outstanding | 3,618 | 3,701 | 3,618 | 3,701 |